NCT01617967 - Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

January 31, 2014

Conditions

TTR-mediated Amyloidosis

Interventions

DRUG

Patisiran

Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.

Trial Locations (10)

Unknown

Clinical Trial Site, Boston

Clinical Trial Site, Rio de Janeiro

Clinical Trial Site, Le Kremlin-Bicêtre

Clinical Trial Site, Marseille

Clinical Trial Site, Münster

Clinical Trial Site, Lisbon

Clinical Trial Site, Porto

Clinical Trial Site, Barcelona

Clinical Trial Site, Palma de Mallorca

Clinical Trial Site, Umeå